The UK sets a record 22.9% payment rate under the 2025 VPAG for branded medicines, sparking criticism from the pharma industry. The ABPI warns the increase threatens industry growth and the UK’s ...
Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk ...
Novo Nordisk (NVO) has reportedly been criticized by the U.K.'s Prescription Medicines Code of Practice Authority, or PMCPA, for mischaracterizing certain payments to patients and healthcare groups.
"It’s essential that the ABPI is seen as innovative and up to speed with technologies used across the digital spectrum, not only to align with the changes its members are implementing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback